Patents by Inventor Théophile OHLMANN

Théophile OHLMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND PRODUCTS FOR GENETIC ENGINEERING
    Publication number: 20240132547
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: April 2, 2023
    Publication date: April 25, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • METHODS AND PRODUCTS FOR GENETIC ENGINEERING
    Publication number: 20240109940
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 4, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Methods and products for genetic engineering
    Patent number: 11649264
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: May 16, 2023
    Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite De Claude Bernard Lyon 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • METHODS AND PRODUCTS FOR GENETIC ENGINEERING
    Publication number: 20210284697
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 16, 2021
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Methods and products for genetic engineering
    Patent number: 10968253
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • METHODS AND PRODUCTS FOR GENETIC ENGINEERING
    Publication number: 20190055288
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 21, 2019
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Cell-Free Translation System
    Publication number: 20150376673
    Abstract: The present invention relates to a new cell-free translation system. In particular, the invention relates to a cell-free reaction system for translating in vitro a RNA into a protein, said reaction system comprising a ribosome-depleted red blood cell lysate and ribosomes isolated from eukaryotic cells, with the proviso that (1) when the ribosome-depleted red blood cell lysate is obtained from a nuclease untreated rabbit reticulocyte lysate, the eukaryotic cells from which ribosomes are isolated are not nuclease untreated rabbit reticulocytes, and (2) when the ribosome-depleted red blood cell lysate is obtained from a nuclease treated rabbit reticulocyte lysate, the eukaryotic cells from which ribosomes are isolated are not nuclease treated rabbit reticulocytes. The invention also pertains to a method for translating in vitro a ribonucleic acid template into an amino acid sequence of interest using the cell-free reaction system of the invention.
    Type: Application
    Filed: February 6, 2014
    Publication date: December 31, 2015
    Inventors: Laurent Balvay, Didier Decimo, Baptiste Panthu, Theophile Ohlmann